FDA Rejects Replimune's Melanoma Drug RP1 Again
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy REPL?
Source: stocktwits
- FDA Rejection: The FDA has once again refused to approve Replimune's melanoma drug RP1 this month, citing insufficient data to provide “substantial evidence of effectiveness,” which significantly impacts Replimune's market prospects.
- Call for Change: Melanoma doctors criticized the FDA's decision in an opinion piece in The Wall Street Journal, noting that the initial review panel recommended approval, but this was overruled by the FDA's biologics chief, highlighting inconsistencies in FDA decision-making.
- Market Reaction: Despite the FDA's rejection, Replimune's shares surged 22% after doctors expressed disappointment, indicating that there remains potential demand for the drug and support from the medical community.
- Future Outlook: Replimune has the option to resubmit or withdraw its application within a year, and the FDA's rejection has not changed, making future clinical trials and data critical to determining the drug's fate.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REPL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REPL
Wall Street analysts forecast REPL stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 1.860
Low
3.00
Averages
11.43
High
18.00
Current: 1.860
Low
3.00
Averages
11.43
High
18.00
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Rejects Replimune's Melanoma Drug RP1 Again
- FDA Rejection: The FDA has once again refused to approve Replimune's melanoma drug RP1 this month, citing insufficient data to provide “substantial evidence of effectiveness,” which significantly impacts Replimune's market prospects.
- Call for Change: Melanoma doctors criticized the FDA's decision in an opinion piece in The Wall Street Journal, noting that the initial review panel recommended approval, but this was overruled by the FDA's biologics chief, highlighting inconsistencies in FDA decision-making.
- Market Reaction: Despite the FDA's rejection, Replimune's shares surged 22% after doctors expressed disappointment, indicating that there remains potential demand for the drug and support from the medical community.
- Future Outlook: Replimune has the option to resubmit or withdraw its application within a year, and the FDA's rejection has not changed, making future clinical trials and data critical to determining the drug's fate.
See More
FDA Rejects Replimune's RP1 Drug Candidate Amid Market Capitalization Loss
- FDA Rejection: The FDA has rejected Replimune's lead candidate RP1 for the second time in less than a year, aimed at treating melanoma, resulting in a market capitalization loss of over 50% since April 10.
- Political Interference Statement: U.S. Health and Human Services Secretary Robert F. Kennedy Jr. stated during a Senate hearing that he had no involvement in the FDA's decision, emphasizing the trustworthiness of the FDA's decision-making process.
- FDA Official Responsibility: Kennedy cited FDA Commissioner Marty Makary as the key official responsible for the rejection, noting that every panel reviewing the drug unanimously voted against it, citing its apparent ineffectiveness.
- Market Reaction: Following the FDA's rejection, Replimune's shares plummeted by 56%, hitting an all-time low, indicating a pessimistic outlook from the market regarding the company's future prospects.
See More
Pomerantz LLP Investigates Replimune for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors.
- Negative FDA Response: On April 10, 2026, the U.S. FDA issued a complete response letter to Replimune, stating that the data for its Biologics License Application for RP1 in combination with nivolumab was insufficient to demonstrate effectiveness, directly impacting the company's future drug development prospects.
- Stock Price Plunge: Following the FDA's negative news, Replimune's stock price fell by $3.06, or 64.28%, closing at $1.70 per share on April 13, 2026, reflecting extreme pessimism in the market regarding its future performance.
- Legal Action Risks: Due to potential securities fraud allegations, Replimune faces the risk of class action lawsuits, which could impose significant legal and financial pressures on the company, affecting its operations and investor confidence.
See More
REPL Faces Pressure After FDA Issues Second Complete Response Letter
- Regulatory Pressure on REPL: REPL's stock plummeted 64% after the FDA issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with nivolumab for anti-PD-1-failed melanoma, highlighting a lack of alignment with the FDA and prompting widespread analyst downgrades across Wall Street.
- HOTH Financing Impact: HOTH's stock declined 1% following the announcement of a $2 million stock offering priced at $0.70 per share, overshadowing positive pipeline updates for its HT-001 therapy, which showed significant efficacy in treating skin toxicities, indicating market concerns over dilution.
- ONCO's Stock Slide: ONCO's shares fell 27% after implementing a 1-for-5 reverse stock split to comply with Nasdaq's minimum bid price requirement, despite ongoing efforts to acquire Realbotix in an all-stock deal, reflecting investor anxiety over compliance pressures.
- Retail Investor Sentiment: Retail sentiment on Stocktwits showed REPL as 'bearish' while HOTH and ONCO were 'extremely bullish', indicating a divergence in market sentiment despite all three stocks underperforming the broader XLV ETF over the past year, with declines of 77%, 36%, and 97% respectively.
See More
Replimune Faces FDA CRL for RP1 Melanoma Therapy Amid Analyst Downgrades
- FDA Rejection Impact: Replimune's RP1 melanoma therapy received a Complete Response Letter (CRL) from the FDA, indicating significant hurdles in obtaining market approval, which could lead to a decline in future revenue expectations for the company.
- Analyst Downgrades: Following the FDA rejection, analysts have sharply cut their ratings and price targets for Replimune, reflecting a pessimistic sentiment regarding the company's future prospects, which may further undermine investor confidence.
- Review Process Dispute: Replimune has disputed the FDA's review process, claiming unfairness, which could lead to further communications with the regulatory body and impact the company's future approval strategies.
- Negative Market Reaction: The combination of the FDA rejection and negative analyst feedback may put pressure on Replimune's stock price, prompting investors to closely monitor how the company addresses this challenge to restore market confidence.
See More
Replimune Shares Hit All-Time Low After FDA Rejection
- FDA Rejection: Replimune's melanoma drug RP1 received a Complete Response Letter from the FDA on April 10, causing shares to plummet to an all-time low of $1.50 on Monday, reflecting a negative market sentiment towards the company's future prospects.
- Analyst Downgrades: J.P. Morgan, BMO Capital Markets, and Wedbush have all downgraded Replimune, with BMO's Evan David Seigerman setting a price target of $1, indicating a lack of confidence in RP1's potential for approval.
- Clinical Trial Uncertainty: Analysts noted that the FDA expressed concerns regarding Replimune's BLA resubmission, particularly criticizing the single-arm trial design and efficacy assessment methods used in the RPL-001-16 trial, which raises the risk of RP1's future approval.
- Severe Market Reaction: Following the FDA's rejection, Replimune's stock fell by 56% on Monday, demonstrating a significant loss of investor confidence that could adversely affect the company's financing and research capabilities.
See More
FDA Rejects Replimune's Melanoma Drug RP1 Again
- FDA Rejection: The FDA has once again refused to approve Replimune's melanoma drug RP1 this month, citing insufficient data to provide “substantial evidence of effectiveness,” which significantly impacts Replimune's market prospects.
- Call for Change: Melanoma doctors criticized the FDA's decision in an opinion piece in The Wall Street Journal, noting that the initial review panel recommended approval, but this was overruled by the FDA's biologics chief, highlighting inconsistencies in FDA decision-making.
- Market Reaction: Despite the FDA's rejection, Replimune's shares surged 22% after doctors expressed disappointment, indicating that there remains potential demand for the drug and support from the medical community.
- Future Outlook: Replimune has the option to resubmit or withdraw its application within a year, and the FDA's rejection has not changed, making future clinical trials and data critical to determining the drug's fate.
See More
FDA Rejects Replimune's RP1 Drug Candidate Amid Market Capitalization Loss
- FDA Rejection: The FDA has rejected Replimune's lead candidate RP1 for the second time in less than a year, aimed at treating melanoma, resulting in a market capitalization loss of over 50% since April 10.
- Political Interference Statement: U.S. Health and Human Services Secretary Robert F. Kennedy Jr. stated during a Senate hearing that he had no involvement in the FDA's decision, emphasizing the trustworthiness of the FDA's decision-making process.
- FDA Official Responsibility: Kennedy cited FDA Commissioner Marty Makary as the key official responsible for the rejection, noting that every panel reviewing the drug unanimously voted against it, citing its apparent ineffectiveness.
- Market Reaction: Following the FDA's rejection, Replimune's shares plummeted by 56%, hitting an all-time low, indicating a pessimistic outlook from the market regarding the company's future prospects.
See More
Pomerantz LLP Investigates Replimune for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors.
- Negative FDA Response: On April 10, 2026, the U.S. FDA issued a complete response letter to Replimune, stating that the data for its Biologics License Application for RP1 in combination with nivolumab was insufficient to demonstrate effectiveness, directly impacting the company's future drug development prospects.
- Stock Price Plunge: Following the FDA's negative news, Replimune's stock price fell by $3.06, or 64.28%, closing at $1.70 per share on April 13, 2026, reflecting extreme pessimism in the market regarding its future performance.
- Legal Action Risks: Due to potential securities fraud allegations, Replimune faces the risk of class action lawsuits, which could impose significant legal and financial pressures on the company, affecting its operations and investor confidence.
See More
REPL Faces Pressure After FDA Issues Second Complete Response Letter
- Regulatory Pressure on REPL: REPL's stock plummeted 64% after the FDA issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with nivolumab for anti-PD-1-failed melanoma, highlighting a lack of alignment with the FDA and prompting widespread analyst downgrades across Wall Street.
- HOTH Financing Impact: HOTH's stock declined 1% following the announcement of a $2 million stock offering priced at $0.70 per share, overshadowing positive pipeline updates for its HT-001 therapy, which showed significant efficacy in treating skin toxicities, indicating market concerns over dilution.
- ONCO's Stock Slide: ONCO's shares fell 27% after implementing a 1-for-5 reverse stock split to comply with Nasdaq's minimum bid price requirement, despite ongoing efforts to acquire Realbotix in an all-stock deal, reflecting investor anxiety over compliance pressures.
- Retail Investor Sentiment: Retail sentiment on Stocktwits showed REPL as 'bearish' while HOTH and ONCO were 'extremely bullish', indicating a divergence in market sentiment despite all three stocks underperforming the broader XLV ETF over the past year, with declines of 77%, 36%, and 97% respectively.
See More
Replimune Faces FDA CRL for RP1 Melanoma Therapy Amid Analyst Downgrades
- FDA Rejection Impact: Replimune's RP1 melanoma therapy received a Complete Response Letter (CRL) from the FDA, indicating significant hurdles in obtaining market approval, which could lead to a decline in future revenue expectations for the company.
- Analyst Downgrades: Following the FDA rejection, analysts have sharply cut their ratings and price targets for Replimune, reflecting a pessimistic sentiment regarding the company's future prospects, which may further undermine investor confidence.
- Review Process Dispute: Replimune has disputed the FDA's review process, claiming unfairness, which could lead to further communications with the regulatory body and impact the company's future approval strategies.
- Negative Market Reaction: The combination of the FDA rejection and negative analyst feedback may put pressure on Replimune's stock price, prompting investors to closely monitor how the company addresses this challenge to restore market confidence.
See More
Replimune Shares Hit All-Time Low After FDA Rejection
- FDA Rejection: Replimune's melanoma drug RP1 received a Complete Response Letter from the FDA on April 10, causing shares to plummet to an all-time low of $1.50 on Monday, reflecting a negative market sentiment towards the company's future prospects.
- Analyst Downgrades: J.P. Morgan, BMO Capital Markets, and Wedbush have all downgraded Replimune, with BMO's Evan David Seigerman setting a price target of $1, indicating a lack of confidence in RP1's potential for approval.
- Clinical Trial Uncertainty: Analysts noted that the FDA expressed concerns regarding Replimune's BLA resubmission, particularly criticizing the single-arm trial design and efficacy assessment methods used in the RPL-001-16 trial, which raises the risk of RP1's future approval.
- Severe Market Reaction: Following the FDA's rejection, Replimune's stock fell by 56% on Monday, demonstrating a significant loss of investor confidence that could adversely affect the company's financing and research capabilities.
See More
